Accelerated approval pathways are regulatory mechanisms that facilitate the early access of promising new drugs to patients, particularly those with serious or life-threatening conditions such as cancer. These pathways allow the use of surrogate endpoints to expedite the approval process, thus bringing potentially life-saving treatments to the market more quickly.
